Zacks Investment Research upgraded shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) from a sell rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. “

A number of other equities analysts have also commented on the company. Deutsche Bank AG reissued a buy rating and issued a $255.00 price objective on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. TheStreet lowered Bio-Rad Laboratories from a b rating to a c+ rating in a research note on Thursday, August 3rd. Jefferies Group LLC reissued a buy rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an outperform rating and a $250.00 price objective on the stock. Finally, BidaskClub raised Bio-Rad Laboratories from a hold rating to a buy rating in a research note on Thursday, June 22nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $240.00.

Shares of Bio-Rad Laboratories (NYSE BIO) traded down 1.316% on Wednesday, hitting $222.405. The stock had a trading volume of 104,325 shares. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 439.536 and a beta of 0.91. The firm has a 50 day moving average price of $220.90 and a 200-day moving average price of $219.90. Bio-Rad Laboratories has a 52 week low of $154.89 and a 52 week high of $242.79.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/bio-rad-laboratories-inc-bio-upgraded-by-zacks-investment-research-to-hold.html.

In other news, EVP Michael Crowley sold 700 shares of the company’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 28.29% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Bio-Rad Laboratories by 0.3% during the second quarter. BlackRock Inc. now owns 1,738,431 shares of the medical research company’s stock valued at $393,424,000 after acquiring an additional 5,320 shares during the period. Vanguard Group Inc. lifted its stake in shares of Bio-Rad Laboratories by 0.4% during the second quarter. Vanguard Group Inc. now owns 1,679,405 shares of the medical research company’s stock valued at $380,067,000 after acquiring an additional 6,131 shares during the period. FMR LLC lifted its stake in shares of Bio-Rad Laboratories by 237.4% during the second quarter. FMR LLC now owns 711,313 shares of the medical research company’s stock valued at $160,978,000 after acquiring an additional 500,513 shares during the period. TimesSquare Capital Management LLC lifted its stake in shares of Bio-Rad Laboratories by 1.6% during the second quarter. TimesSquare Capital Management LLC now owns 621,650 shares of the medical research company’s stock valued at $140,686,000 after acquiring an additional 9,950 shares during the period. Finally, State Street Corp lifted its stake in shares of Bio-Rad Laboratories by 1.7% during the second quarter. State Street Corp now owns 545,232 shares of the medical research company’s stock valued at $123,396,000 after acquiring an additional 8,865 shares during the period. 62.84% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.